Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.
Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.
The company's shares jumped 4% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.